<DOC>
	<DOCNO>NCT00091663</DOCNO>
	<brief_summary>This Phase IIIb , multicenter , open-label trial daily oral Tarceva patient advance ( inoperable Stage IIIb IV ) NSCLC progress follow standard chemotherapy treatment .</brief_summary>
	<brief_title>A Study Evaluate Tarceva Patients With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Written ( sign ) inform consent ( ) Inoperable incurable , locally advanced , recurrent metastatic NSCLC Relapse follow standard chemotherapy ( combination chemotherapy twodrug combination chemotherapy , singleagent chemotherapy agent elderly poor performance status patient ) Age &gt; =18 year ECOG performance status 0 3 Recovered toxic effect prior therapy Able comply study followup procedure Able take oral medication Use effective mean contraception ( patient reproductive potential ) Granulocyte count &gt; =1.0 x 10^9/L Platelet count &gt; =75 x 10^9/L Serum bilirubin &lt; 1.5 x upper limit normal ( ULN ) SGOT ( AST ) &lt; 2 x ULN unless elevation clearly due liver metastasis ; SGOT ( AST ) must &lt; 5 x ULN Serum creatinine &lt; =1.5 mg/dL Any unstable systemic disease ( include active infection , unstable angina , congestive heart failure , myocardial infarction within last 6 month , hepatic , renal , metabolic disease ) Prior therapy systemic HER1/EGFR small molecule inhibitor , include gefitinib ( Iressa ) , erlotinib ( Tarceva ) , investigational agent class History another malignancy past 2 year unless malignancy adequately treat associated 5year anticipated survival &gt; =90 % Known central nervous system ( CNS ) metastases yet definitively treat surgery and/or radiation symptomatic unstable Nursing mother pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Advanced non-small cell lung cancer</keyword>
</DOC>